Document is current
Any future updates will be listed below
-
Authors
Knudsen, Hannah K.
Back-Haddix, Sandra
Andrews-Higgins, Shaquita
Goetz, Michael
Davis, Olivia A.
Oyler, Douglas R.
Walsh, Sharon L.
Freeman, Patricia R.
-
Funding
Funding for this research was provided by:
National Institutes of Health and the Substance Abuse and Mental Health Services Administration (UM1DA049406, UM1DA049406, UM1DA049406, UM1DA049406, UM1DA049406, UM1DA049406, UM1DA049406)
- License Information
-
More Information
Article History
Received: 16 September 2024
Accepted: 27 February 2025
First Online: 14 March 2025
Declarations
:
: This study protocol (Pro00038088) was approved by Advarra Inc., the HEALing Communities Study single Institutional Review Board. All participants provided verbal informed consent prior to being interviewed.
: Not applicable.
: HKK, SAH, SBH, MG, OD, PRF, and DRO declare that they have no competing interests. SLW has served as a scientific advisor/consultant for Opiant Pharmaceuticals and Pocket Naloxone.
